Perrigo Settles Patent Litigation For Generic Version Of Finacea Foam, 15%

(RTTNews) - Perrigo Co. plc (PRGO) said Tuesday that it has settled its Hatch-Waxman litigation relating to its tentatively-approved generic version of Finacea Foam (azelaic acid) 15% pursued by LEO Pharma A/S, LEO Pharma Inc., and Foamix Pharmaceuticals Ltd. The company noted that terms of the settlement are confidential.

As measured by IQVIA, annual market sales for the 12 months ending February 2019 were about $61 million.

"This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to advance our pipeline of specialized generic products that provide high quality alternatives, and savings to patients and payors," said Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PRGO